Apotex Health Plans $1B IPO on TSX, Valuing Generic Drugmaker at $5B

By Huzaifa Zahoor

June 3, 2026

08:21 AM

2 min read

Share with:

preferred News SourceSelectMeykaasyourpreferredNewsSource

Key Points

Apotex launches $1B IPO on TSX at C$20-C$24 per share.

Company valued at approximately $5 billion.

Raises C$850M new shares and C$150M from existing shareholders.

Revenue grew 8% over four fiscal years in generics business.

Be the first to rate this article

Apotex Health Corp. announced a $1 billion initial public offering on June 1, 2026, marking the first major IPO on the Toronto Stock Exchange this year. The company plans to sell between 41.7 million and 50 million shares at C$20 to C$24 per share, valuing the generic drug manufacturer at approximately $5 billion. The deal could help revive Canada’s stalled IPO market after limited listings in recent years.

IPO Structure and Pricing

Apotex plans to raise roughly C$850 million through new share issuance and C$150 million from existing shareholders selling stock. The company expects to offer between 41.7 million and 50 million shares at C$20 to C$24 per share, with gross proceeds of C$1 billion. Underwriters include RBC Capital Markets, TD Securities, Scotiabank, BMO Capital Markets, and Jefferies as joint bookrunners.

Business Profile and Growth

Toronto-based Apotex serves clients in approximately 70 countries across North and South America. The company recorded revenue growth of about 8% over the last four fiscal years, driven by its core generics business. Apotex focuses on first-to-market products and has expanded into higher-value areas including specialty generics, brands, and biosimilars.

Market Revival Signal

The IPO comes as renewed economic confidence and a rising Toronto Stock Exchange attract companies back to public markets. Earlier in 2026, quantum computing firm Xanadu Quantum Technologies went public through a merger with a special purpose acquisition company, raising about $300 million. Apotex represents one of the first major offerings from the healthcare and pharmaceutical sectors in the current cycle.

Final Thoughts

Apotex’s $1 billion IPO signals renewed confidence in Canada’s capital markets after years of weakness. With a $5 billion valuation and strong revenue growth, the deal could attract more healthcare companies to list on the TSX.

FAQs

What price range is Apotex offering shares at?

Apotex is offering shares at C$20 to C$24 per share, targeting C$1 billion in gross proceeds.

How much revenue has Apotex grown over the past four years?

Apotex achieved approximately 8% revenue growth over four fiscal years, primarily from its core generics business.

Which countries does Apotex serve?

Apotex serves clients across approximately 70 countries in North and South America.

Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.

About Author

Huzaifa Zahoor

Co Founder

Huzaifa Zahoor is the engineer who built Meyka. He has spent years writing Python, training AI models, and building data pipelines specifically for financial markets. His technical articles have reached over 30,000 readers on Medium, so he knows how to make complex things easy to follow. If this article touches on how the tools work, he is the person who actually built them.